Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Total Liabilities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Total Liabilities for 17 consecutive years, with $156.6 million as the latest value for Q1 2026.

  • Quarterly Total Liabilities fell 3.22% to $156.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $156.6 million through Jan 2026, down 3.22% year-over-year, with the annual reading at $156.6 million for FY2026, 3.22% down from the prior year.
  • Total Liabilities for Q1 2026 was $156.6 million at Usana Health Sciences, up from $145.0 million in the prior quarter.
  • The five-year high for Total Liabilities was $183.0 million in Q2 2022, with the low at $119.2 million in Q2 2024.
  • Average Total Liabilities over 5 years is $149.4 million, with a median of $149.0 million recorded in 2025.
  • The sharpest move saw Total Liabilities dropped 19.4% in 2022, then grew 25.86% in 2025.
  • Over 5 years, Total Liabilities stood at $162.1 million in 2022, then dropped by 16.36% to $135.6 million in 2023, then rose by 19.41% to $161.9 million in 2024, then dropped by 10.39% to $145.0 million in 2025, then grew by 8.0% to $156.6 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $156.6 million, $145.0 million, and $149.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.